XX RBS Morgans

1 December 2011

BUY

Important: The above recommendation has been made on a 12 month view and may not suit your investment needs or timeframe. The basis it is prepared on is summarised on the last page of this report. PLEASE CONTACT YOUR ADVISER TO DISCUSS THIS GENERAL RECOMMENDATION BEFORE ACTING ON IT.

High Volatility

Target price A\$0.07

Price A\$0.037

Market capitalisation A\$44.5m

SHC111201

Priced at close of business 30 November 2011. Source: IRESS

Sunshine Heart Inc

Easing the squeeze

Last month Dr William T. Abraham presented details of a 20-patient feasibility trial for SHC's C-Pulse device at the Transcatheter Cadiovacular Therapeutics Conference in San Francisco. All but one patient remained unchanged or demonstrated improvement in key evaluative endpoints. Buy maintained.

Sunshine Heart Inc - Milestone Table

Event	Timing	Impact
FDA Feasibility Trial - Finish recruitment	Achieved	Positive
Cuff changes complete for minimally invasive surgery	Achieved	Positive
FDA Feasibility Trial – Six month follow up	Achieved	Positive
New single unit driver released	Achieved	Positive
FDA Pivotal Trial protocol approval	1QCY12	Positive
CE Mark Approval	1QCY12	Positive
FDA Pivotal Trial Commence	2QCY12	Positive
NASDAQ listing	4QCY11 (was 3QCY11)	Positive

Source: RBS Morgans & Company Data

Feasibility trial results are promising

In a presentation to analysts and health professionals at the Transcatheter Cardiovascular Therapeutics Conference held in San Fransisco, Dr William T Abraham provided details of SHC's FDA-approved feasibility trial for the C-Pulse Heart Assist System. After six months follow-up, C–Pulse therapy produced statistically significant improvements in NYHA Class reduction (3.1±0.3 to 2.2±0.8, P=0.0001), Quality of Life (64±17 to 49±26, P=0.001), and Left Ventricular Ejection Fraction (28±5 to 31±7, P=0.04). All but one patient remained unchanged or demonstrated improvement in NYHA, Minnesota Living With Heart Failure (MLWHF) quality of life and Six Minute Hall Walk (6MHW). In addition, four patients improved to NYHA Class I and two patients were permanently removed from therapy due to improvements. These preliminary results are encouraging, and should be sufficient to warrant a subsequent pivotal trial.

Pivotal trial, CE Mark plans on track

SHC will submit the feasibility data to the FDA seeking approval for a larger pivotal study, flagged to commence in 2QCY12. The pivotal study is estimated to involve 250 – 300 patients, as a precursor to marketing C-Pulse in the US. We expect that the study would be randomised against existing medical therapy. SHC will also use the feasibility data to apply for CE Mark approval for the C-Pulse to be marketed in the European Union and other countries accepting CE Mark. Management have said that they are on track on file for the CE Mark this month, and expect approval could be achieved as early as 1HCY12.

Investment View: Buy maintained - Price Target A\$0.07

We have made no adjustments to our forecasts. Therefore, our DCF valuation remains at A\$0.09 and our price target remains at A\$0.07. The key risk lies in securing adequate funding to maintain momentum for the pivotal trial. Buy maintained.

Analysts

Scott Power +61 7 3334 4884 scott.power@rbsmorgans.com

SHC111201

RBS Morgans Limited (A.B.N. 49 010 669 726) AFSL235410 A Participant of ASX Group


www.rbsmorgans.com

Full results announced at TCT conference

Last month Dr William Abraham, co-lead principal investigator for the C-Pulse Heart Assist System feasibility trial, presented his results to healthcare professionals and analysts at the Transcatheter Cardiovascular Therapeutics Conference held in San Francisco. The multi-center trial involved twenty patients - 8 women and 12 men with an average age of 56 (ranging 34-71). Eighteen patients were classified with New York Heart Association (NYHA) Class III heart failure and two were Class IV, the most severe forms of heart failure. For these patients, daily activities such as walking across the room, moderate exercise or climbing stairs can be a challenge. All patients had cardiac resynchronization therapy, implantable cardiac defibrillators or combination devices implanted. Three patients were successfully bridged to transplant with one patient being supported for 22 months, the longest of any patient participating in the trial.

All but one patient either improved or maintained NYHA heart failure classification. Two patients were disconnected permanently, one after eleven months on therapy due to the absence of heart failure symptoms. One of the patients that was removed permanently was a Class IV patient when the trial commenced. This result, in Dr Abraham's own words, is "remarkable". After six months follow-up, C–Pulse therapy produced statistically significant improvements in NYHA Class reduction (3.1±0.3 to 2.2±0.8, P=0.0001), Quality of Life (64±17 to 49±26, P=0.001), and Left Ventricular Ejection Fraction (28±5 to 31±7, P=0.04) which measures the heart's pumping ability. All but one patient remained unchanged or demonstrated improvement in NYHA, Minnesota Living With Heart Failure (MLWHF) quality of life and Six Minute Hall Walk (6MHW).No neurologic events or heart attacks were reported, while six superficial exit site infections were successfully treated with antibiotics. There was one instance of post operative, non-device related bleeding.

Chart 1: Feasibility trial results



Source: Company presentation

Death clarified, steps taken to mitigate subsequent fatalities

One patient death from an aortic disruption was reported as a result of a re-sternotomy surgery to treat a procedure related infection. The death occurred in the setting of a sternal wound infection; which can arise when surgery requires the opening up of the sternum to access the chest cavity. Typically, if a sternal infection is identified the surgeon will reoperate immediately to clean out the infection and also treat the patient with antibiotics. In the case of the patient who died, the surgeon chose only to treat the patient with antibiotics. When the infection progressed four months later, the surgeon operated to treat the infection and remove the device, and tore the patient's aorta in the process. Notably, Dr Abraham emphasised that the death was due to an avoidable complication and said that steps were being taken to ensure that a similar event will not reoccur in subsequent trials.

Key Milestones

As always the share price performance is usually directly correlated with achievement of key milestones (refer to Table 1). SHC Chief Executive officer, Dave Rosa, indicated that new modified versions of the C-Pulse device, including a single unit system, would be available by the end of October.

Table 1 – Milestones to focus on		
Event	Timing	Impact
FDA Feasibility Trial - Finish recruitment	Achieved	Positive
Cuff changes complete for minimally invasive surgery	Achieved	Positive
FDA Feasibility Trial – Six month follow up	Achieved	Positive
New single unit driver released	Achieved	Positive
FDA Pivotal Trial protocol approval	1QCY12	Positive
CE Mark Approval	1QCY12	Positive
FDA Pivotal Trial Commence	2QCY12	Positive
NASDAQ listing	4QCY11 (was 3QCY11)	Positive
FDA Pivotal Trial Complete	1QCY14	Very Positive
Pivotal Trial Follow Up	1QCY15	Positive
PMA application	2QCY15	Very Positive
Commercial Sales C-Pulse	1QCY16	Very Positive

Source: RBS Morgans & Company Data

The next step - pivotal trial

SHC will submit the feasibility data to the FDA seeking approval for a larger pivotal study. In addition, the FDA has allowed SHC to continue to enrol patients under its feasibility trial protocol potentially implanting up to another 20 patients. SHC will also use the feasibility data to apply for CE Mark approval for the C-Pulse to be marketed in the European Union and other countries accepting CE Mark, expected early next year.

The pivotal study is estimated to involve 250 – 300 patients, as a precursor to marketing C-Pulse in the US. We expect that the study would be randomised against existing medical therapy. Once the pivotal trial begins, SHC will no longer enrol under the feasibility trial. SHC is planning to meet with the US Food & Drug Administration (FDA) in January 2012 to discuss the clinical data, final design and protocol for the US Pivotal trial. Patient recruitment is anticipated to begin in mid-2012.

Investment View: Buy for near term milestone

We have made no changes to our forecasts and our valuation remains A\$0.09. We have maintained our short term price target at A\$0.07. The key risk is securing additional funding for the larger pivotal trial which is expected to start 2QCY12. It is estimated that US\$35m to US\$40m will be required for this trial. We have maintained our Buy recommendation for investors with a higher risk profile.

SHC: Financial summary

Income statement	AIFRS 2009A	AIFRS 2010A	AIFRS 2011A	AIFRS 2012F	AIFRS 2013F	AIFRS 2014F	Closing price (A\$) Valuation metrics	0.037	Price	target (A\$)	0.07
Divisional sales	0.1	0.3	0.3	2.2	3.2	7.1	Preferred methodology	DCF		Val'n (A\$)	\$0.09
Total revenue	0.1	0.3	0.3	2.2	3.2	7.1	DCF valuation inputs			,	
EBITDA	-8.4	-7.4	-11.7	-15.8	-15.4	-13.1	Rf .	5.25%	1	0-year rate	5.25%
Associate income	0.0	0.0	0.0	0.0	0.0	0.0	R m-Rf	6.00%	N	largin	2.0%
Depreciation	0.1	0.1	0.0	0.0	0.0	0.0	Beta	1.80	K	d	16.05%
EBITA	-8.4	-7.5	-11.8	-15.8	-15.5	-13.1	CAPM (Rf+Beta(Rm-Rf))	16.1%	K	e	16.1%
Amortisation/impairment	0.0	0.0	0.0	0.0	0.0	0.0	E/EV*Ke+D/EV*Kd(1-t)	N	PV cash flow	(A\$m)	165.5
EBIT	-8.4	-7.5	-11.8	-15.8	-15.5	-13.1	Equity (E/EV)	100.0% N	linority interes	st (A\$m)	0.0
EBIT(incl associate profit)	-8.4	-7.5	-11.8	-15.8	-15.5	-13.1	Debt (D/EV)	0.0% N	et debt (A\$m)	-2.8
Net interest expense	-0.3	-0.2	-0.3	-0.4	-0.8	-0.8	Interest rate	16.05% In	vestments (A	\$m)	0.0
Pre-tax profit	-8.1	-7.3	-11.5	-15.4	-14.7	-12.3	Tax rate (t)	30.0% E	quity market	/alue (A\$m)	168.3
Income tax expense	0.0	-0.8	0.0	0.0	0.0	0.0	WACC	16.1% D	iluted no. of s	hares (m)	1780.9
After-tax profit	-8.1	-6.5	-11.5	-15.4	-14.7	-12.3				F valuation	\$0.09
Minority interests	0.0	0.0	0.0	0.0	0.0	0.0					
NPAT	-8.1	-6.5	-11.5	-15.4	-14.7	-12.3	Multiples	2010A	2011A	2012F	2013F
Significant items	0.0	0.0	0.0	0.0	0.0	0.0	Enterprise value (A\$m)	63.9	62.0	59.9	52.5
NPAT post abnormals	-8.1	-6.5	-11.5	-15.4	-14.7	-12.3	EV/Sales (x)	na	191.2	26.9	16.2
							EV/EBITDA (x)	-8.6	-5.3	-3.8	-3.4
Cash flow statement	2009A	2010A	2011A	2012F	2013F	2014F	EV/EBIT (x)	-8.5	-5.3	-3.8	-3.4
EBITDA	-8.4	-7.4	-11.7	-15.8	-15.4	-13.1	PE (pre-goodwill) (x)	-3.0	-3.2	-3.5	-4.0
	0.3	-0.8			-0.2		(pro goodwiii) (x)	-5.0	-0.2	-5.5	0
Change in working capital	0.3	-0.8 0.2	1.4 0.3	0.8 0.4	-0.2 0.8	-0.8 0.8					
Net interest (pd)/rec							At target price	2010A	2011A	2012F	2013F
Taxes paid	0.0	0.8	0.0	0.0	0.0	0.0	At target price				
Other oper cash items	0.0	0.0	0.0	0.0	0.0	0.0	EV/EBITDA (x)	-16.7	-10.4	-6.9	-5.6
Cash flow from ops (1)	-7.8	-7.3	-10.1	-14.6	-14.8	-13.1	PE (pre-goodwill) (x)	-5.7	-6.1	-6.5	-7.6
Capex (2)	0.0	0.0	0.0	0.0	0.0	0.0					
Disposals/(acquisitions)	0.0	0.0	0.0	0.0	0.0	0.0	Comparable company data (x)	2010A	2011A	2012F	2013F
Other investing cash flow	0.0	0.0	0.0	0.0	0.0	0.0	Acrux				
Cash flow from invest (3)	0.0	0.0	0.0	0.0	0.0	0.0	EV/EBITDA	8.2	5.2	54.3	8.7
Incr/(decr) in equity	0.0	9.2	12.2	21.5	15.0	0.0	EV/EBIT	8.3	5.4	86.8	9.6
Incr/(decr) in debt	0.0	0.0	0.0	0.0	0.0	0.0	PE	10.0	8.2	86.1	16.7
Ordinary dividend paid	0.0	0.0	0.0	0.0	0.0	0.0	ImpediMed				
Preferred dividends (4)	0.0	0.0	0.0	0.0	0.0	0.0	EV/EBITDA	-4.8	-3.8	-5.3	14.9
Other financing cash flow	0.0	0.0	0.0	0.0	0.0	0.0	EV/EBIT	-4.5	-3.7	-5.1	16.1
Cash flow from fin (5)	0.0	9.2	12.2	21.5	15.0	0.0	PE		na	na	na
Forex and disc ops (6)	0.0	0.0	0.0	0.0	0.0	0.0					114
Inc/(decr) cash (1+3+5+6)	0.0	0.0	0.0	0.0	0.0	0.0	Per share data	2010A	2011A	2012F	2013F
Equity FCF (1+2+4)	-7.8	-7.3	-10.1	-14.6	-14.8	-13.1	No. shares	536.9	1008.9	1438.9	1588.9
Equity FOT (17214)	7.0	7.0	10.1	14.0	14.0	10.1	EPS (cps)	-1.2	-1.1	-1.1	-0.9
Balance sheet	2009A	2010A	2011A	2012F	2013F	2014F	EPS (normalised) (c)	-1.2	-1.1	-1.1	-0.9
Cash & deposits	2.0	3.9	6.0	13.4	13.5	0.4	Dividend per share (c)	0.0	0.0	0.0	0.0
Trade debtors	0.2	0.2	0.0	0.2	0.3	0.4	Dividend payout ratio (%)	0.0%	0.0%	0.0%	0.0%
	0.0	0.0	0.0	0.2	0.5	1.1		0.0%	0.0%	0.0%	0.0%
Inventory							Dividend yield (%)	0.0 %	0.076	0.0 %	0.0 /6
Investments	0.0	0.0	0.0	0.0	0.0	0.0	Oneseth anti-	00404	20444	20405	204.25
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	Growth ratios	2010A	2011A	2012F	2013F
Other intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	Sales growth	141.8%	0.0%	587.5%	45.5%
Fixed assets	0.2	0.1	0.1	0.1	0.1	0.1	Operating cost growth	8.6%	-55.2%	-49.3%	-3.7%
Other assets	0.1	0.9	0.1	0.1	0.1	0.1	EBITDA growth	11.0%	-56.9%	-34.2%	2.2%
Total assets	2.5	5.3	6.4	14.1	14.5	2.3	EBITA growth	11.0%	-56.9%	-34.2%	2.2%
Short-term borrowings	0.0	0.0	0.0	0.0	0.0	0.0	EBIT growth	11.0%	-56.9%	-34.2%	2.2%
Trade payables	0.3	0.5	0.3	1.5	1.5	1.7	NPAT growth	19.6%	-75.9%	-33.6%	4.7%
Long-term borrowings	0.0	0.0	0.0	0.0	0.0	0.0	Pre-goodwill NPAT growth	19.6%	-75.9%	-33.6%	4.7%
Provisions	0.0	0.0	0.0	0.0	0.0	0.0	Pre-goodwill EPS growth	15.8%	91.0%	1126.5%	-94.4%
Other liabilities	0.1	0.1	0.2	0.2	0.2	0.2	Normalised EPS growth	15.8%	91.0%	1126.5%	-94.4%
Total liabilities	0.4	0.5	0.5	1.7	1.8	1.9					
Share capital	48.3	57.5	69.8	75.9	76.2	63.9	Operating performance	2010A	2011A	2012F	2013F
Other reserves	1.8	1.8	2.1	2.1	2.1	2.1	Asset turnover (%)	2.1	1.4	5.4	5.6
Retained earnings	-48.0	-54.6	-66.0	-66.0	-66.0	-66.0	EBITDA margin (%)	na	-3619.5	-707.9	-476.1
	-40.0		0.0	0.0	0.0	0.0	EBIT margin (%)	na	-3632.2	-709.2	-477.1
Other equity	0.0	0.0			12.3	0.0	Net profit margin (%)	na	-3553.8	-690.7	-452.4
	0.0	0.0 4.7		12.0							
Total equity	0.0 2.0	4.7	5.9	12.0 0.0		0.0	Return on net assets (%)	-158.7			-125.5
Total equity Minority interest	0.0 2.0 0.0	4.7 0.0	5.9 0.0	0.0	0.0	0.0 0.0	Return on net assets (%) Net debt (A\$m)	-158.7 -3.9	-200.9	-131.9	-125.5 -13.5
Total equity Minority interest Total shareholders' equity	0.0 2.0 0.0 2.0	4.7 0.0 4.7	5.9 0.0 5.9	0.0 12.0	0.0 12.3	0.0	Net debt (A\$m)	-3.9	-200.9 -6.0	-131.9 -13.4	-13.5
Total equity Minority interest	0.0 2.0 0.0	4.7 0.0	5.9 0.0	0.0	0.0		Net debt (A\$m) Net debt/equity (%)	-3.9 -83.4	-200.9 -6.0 -102.7	-131.9 -13.4 -111.6	-13.5 -109.9
Total equity Minority interest Total shareholders' equity	0.0 2.0 0.0 2.0	4.7 0.0 4.7	5.9 0.0 5.9	0.0 12.0	0.0 12.3	0.0	Net debt (A\$m) Net debt/equity (%) Net interest/EBIT cover (x)	-3.9 -83.4 -43.9	-200.9 -6.0 -102.7 -46.3	-131.9 -13.4 -111.6 -40.6	-13.5 -109.9 -19.3
Total equity Minority interest Total shareholders' equity	0.0 2.0 0.0 2.0	4.7 0.0 4.7	5.9 0.0 5.9	0.0 12.0	0.0 12.3	0.0	Net debt (A\$m) Net debt/equity (%)	-3.9 -83.4	-200.9 -6.0 -102.7	-131.9 -13.4 -111.6	-13.5 -109.9
Total equity Minority interest Total shareholders' equity	0.0 2.0 0.0 2.0	4.7 0.0 4.7	5.9 0.0 5.9	0.0 12.0	0.0 12.3	0.0	Net debt (A\$m) Net debt/equity (%) Net interest/EBIT cover (x)	-3.9 -83.4 -43.9	-200.9 -6.0 -102.7 -46.3	-131.9 -13.4 -111.6 -40.6	-13.5 -109.9 -19.3
Total equity Minority interest Total shareholders' equity	0.0 2.0 0.0 2.0	4.7 0.0 4.7	5.9 0.0 5.9	0.0 12.0	0.0 12.3	0.0	Net debt (A\$m) Net debt/equity (%) Net interest/EBIT cover (x) ROIC (%)	-3.9 -83.4 -43.9 na	-200.9 -6.0 -102.7 -46.3 -10.4	-131.9 -13.4 -111.6 -40.6 -15.0	-13.5 -109.9 -19.3 -15.6
Total equity Minority interest Total shareholders' equity	0.0 2.0 0.0 2.0	4.7 0.0 4.7	5.9 0.0 5.9	0.0 12.0	0.0 12.3	0.0	Net debt (A\$m) Net debt/equity (%) Net interest/EBIT cover (x) ROIC (%) Internal liquid ity	-3.9 -83.4 -43.9 na 2010 A	-200.9 -6.0 -102.7 -46.3 -10.4	-131.9 -13.4 -111.6 -40.6 -15.0	-13.5 -109.9 -19.3 -15.6

Source: RBS Morgans – Share Price as at 30 November 2011



www.rbsmorgans.com

QUEENSLAND		NEWCASTLE	(02) 4926 4044
BRISBANE - HEAD OFFICE	(07) 3334 4888	NEWPORT	(02) 9998 4200
BRISBANE – EDWARD STREET	(07) 3334 4888	ORANGE	(02) 6361 9166
BUNDABERG	(07) 4153 1050	PARRAMATTA	(02) 9615 4500
BURLEIGH HEADS	(07) 5520 8788	PORT MACQUARIE	(02) 6583 1735
CAIRNS	(07) 4222 0555	SCONE	(02) 6544 3144
CALOUNDRA	(07) 5491 5422	WOLLONGONG	(02) 4227 3022
CAPALABA	(07) 3245 5466		
CHERMSIDE	(07) 3350 9000	VICTORIA	
EMERALD	(07) 4988 2777	MELBOURNE – HEAD OFFICE	(03) 9947 4111
GLADSTONE	(07) 4972 8000	MELBOURNE – FARRER HOUSE	(03) 8644 5488
GOLD COAST	(07) 5592 5777	BERWICK	(03) 9796 2676
IPSWICH	(07) 3202 3995	BRIGHTON	(03) 9519 3555
MACKAY	(07) 4957 3033	CAMBERWELL	(03) 9813 2945
MILTON	(07) 3114 8600	CARLTON	(03) 9066 3200
NOOSA	(07) 5449 9511	GEELONG	(03) 5222 5128
REDCLIFFE	(07) 3897 3999	RICHMOND	(03) 9916 4000
ROCKHAMPTON	(07) 4922 5855	SOUTH YARRA	(03) 9098 8511
SPRING HILL	(07) 3833 9333	TRARALGON	(03) 5176 6055
SUNSHINE COAST	(07) 5479 2757	WARRNAMBOOL	(03) 5559 1500
TOOWOOMBA	(07) 4639 1277	Withitelliboot	(00) 0000 1000
TOWNSVILLE	(07) 4725 5787	ACT	
YEPPOON	(07) 4939 3021	CANBERRA	(02) 6232 4999
TEFFOON	(07) 4939 3021	CANDERIVA	(02) 0232 4999
NEW SOUTH WALES		SOUTH AUSTRALIA	
SYDNEY – HEAD OFFICE	(02) 8215 5000		
SYDNEY - MACQUARIE STREET	(02) 9125 1788	ADELAIDE	(08) 8464 5000
SYDNEY - PHILLIP STREET - LEVEL 33	(02) 8215 5111	NO RW OOD	(08) 8461 2800
SYDNEY - REYNOLDS EQUITIES	(02) 9373 4452		(,
ARMIDALE	(02) 6770 3300	WESTERN AUSTRALIA	
BALLINA	(02) 6686 4144	PERTH	(08) 6462 1999
BALMAIN	(02) 8755 3333		(,
CHATSWOOD	(02) 8116 1700	NORTHERN TERRITORY	
COF FS HARBOUR	(02) 6651 5700	DARWIN	(08) 8981 9555
GOSFORD	(02) 4325 0884	D	(55, 555 : 5556
HURSTVILLE	(02) 9570 5755	TASMANIA	
MERIMBULA	(02) 6495 2869	HOBART	(03) 6236 9000
NEUTRAL BAY	(02) 8969 7500		(55) 0200 5000
NEO IIVAE DA I	(02) 0303 7300		

DISCLAIMER - RBS MORGANS LIMITED

The information contained in this report is general advice only, and is made without consideration of an individual's relevant personal circumstances. RBS Morgans Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents ("RBS Morgans") do not accept any liability for the results of any actions taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their RBS Morgans investment adviser before doing so. Those acting upon such information without advice do so entirely at their own risk.

This report was prepared as private communication to clients and is not intended for public circulation, publication or for use by any third party. The contents of this report may not be reproduced in whole or in part without the prior written consent of RBS Morgans. While this report is based on information from sources which RBS Morgans believes are reliable, its accuracy and completeness cannot be guaranteed. Any opinions expressed reflect RBS Morgans judgement at this date and are subject to change. RBS Morgans is under no obligation to provide revised assessments in the event of changed circumstances. This report does not constitute an offer or invitation to purchase any securities and should not be relied upon in connection with any contract or commitment whats oever.

DISCLOSURE OF INTEREST

RBS Morgans may from time to time hold an interest in any security referred to in this report and may, as principal or agent, sell such interests. RBS Morgans may previously have acted as manager or co-manager of a public offering of any such securities. RBS Morgans' affiliates may provide or have provided banking services or corporate finance to the companies referred to in the report. The knowledge of affiliates concerning such services may not be reflected in this report. RBS Morgans advise that it may earn brokerage, commissions, fees or other benefits and advantages, direct or indirect, in connection with the making of a recommendation or a dealing by a client in these securities. Some or all of our Authorised Representatives may be remunerated wholly or partly by way of commission.

REGULATORY DISCLOSURES

RBS Morgans Corporate is the co-lead manager to the Tranche 2 fund raising and may receive fees in this regard. Analyst owns shares.

RECOMMENDATION STRUCTURE

For a full explanation of the recommendation structure, refer to our website at https://www.rbsmorgans.com/research_disclaimer

If you no longer wish to receive RBS Morgans' publications please advise your local RBS Morgans office or write to RBS Morgans Limited, Reply Paid 202, Brisbane QLD 4001 and include your account details.